Changes in US stocks | Q2 earnings report raised concerns about medical technology demand Intuitive Surgery (ISRG.US) plummeted by more than 11% at the beginning of the session

The Zhitong Finance App learned that on Friday, Intuitive Surgery (ISRG.US) plummeted by more than 11% at the beginning of the session, continuing to hit a new low during the year, and is now reporting $357.13. According to the news, Intuitive Surgery released its second-quarter earnings report after the market on Thursday. Revenue and profit both exceeded expectations, but the company maintained the outlook for growth in the number of surgeries throughout the year. At the same time, it warned that changes in US health insurance policies may affect the timing of patients seeking medical treatment, raising market concerns about demand for medical technology.

Financial reports show that second-quarter revenue increased 19% year-on-year to US$2.89 billion, exceeding analysts' expectations of US$2.82 billion; adjusted earnings per share were US$2.80, far exceeding expectations of US$2.51. The total number of surgeries on Da Vinci and Ion platforms worldwide increased by 16%. Among them, the number of Leonardo da Vinci surgeries increased 15% and Ion surgeries increased 36%. However, the slowdown in growth in the US market has raised concerns. The number of Leonardo da Vinci surgeries in the US increased by 12% in the second quarter, lower than the company's expectations at the beginning of the year, mainly in the categories of surgeries that can be postponed. CEO Dave Rosa said during the earnings call that some customers reported that changes in patient insurance coverage and premiums may affect their choice of medical treatment and timing of treatment. The company believes that the expiration of the ACA subsidy had a “mild negative impact” on the increase in the number of Leonardo da Vinci surgeries in the US in the second quarter.

The company maintains the forecast of 13.5% to 15.5% increase in the number of Leonardo da Vinci surgeries in 2026, and the expected growth rate is close to the midpoint of the range. This guidance means that growth will slow somewhat in the second half of the year. Increased competition is also one of the concerns. Medtronic is seeking to expand the range of indications for Hugo's surgical system. Stryker also launched the Mako robot system for total knee replacement this week.